Humacyte Stock Fundamentals
| HUMAW Stock | USD 1.71 0.24 16.33% |
Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.
At this time, Humacyte's Depreciation And Amortization is fairly stable compared to the past year. Cost Of Revenue is likely to climb to about 80.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.1 M in 2024. Humacyte | Select Account or Indicator |
Humacyte Company Number Of Shares Shorted Analysis
Humacyte's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Humacyte Number Of Shares Shorted | 286 |
Most of Humacyte's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Humacyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Humacyte has 286 of outstending shares currently sold short by investors. This is 99.99% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 99.99% higher than that of the company.
Humacyte Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Humacyte competition to find correlations between indicators driving Humacyte's intrinsic value. More Info.Humacyte is rated # 4 in return on equity category among its peers. It also is rated # 4 in return on asset category among its peers . At this time, Humacyte's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Humacyte by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Humacyte Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Humacyte's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics of similar companies.Humacyte is currently under evaluation in number of shares shorted category among its peers.
Humacyte Fundamentals
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Number Of Shares Shorted | 286 | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Total Debt | 58.11 M | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (3.16) X | ||||
| Number Of Employees | 183 | ||||
| Beta | 1.47 | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
| Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -2.4 M | -2.2 M | |
| Cost Of Revenue | 76.5 M | 80.4 M | |
| Stock Based Compensation To Revenue | 3.56 | 3.17 | |
| Sales General And Administrative To Revenue | 13.16 | 8.41 | |
| Research And Ddevelopement To Revenue | 36.38 | 27.50 | |
| Capex To Revenue | 0.77 | 0.65 | |
| Revenue Per Share | 0.02 | 0.02 | |
| Ebit Per Revenue | (62.15) | (65.26) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.